Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 2/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267898 | 0.85 | ADORA2A (0.55) | CDC7CCNE1CDK2DBF4VNN1 | |
| SCHEMBL4528907 | 0.85 | CYP3A4 (0.49) | VNN1CSF1RKITCYP3A4CYP2C19 | |
| SCHEMBL878912 | 0.85 | CSF1R (0.52) | CDC7CCNE1CDK2DBF4VNN1 | |
| SCHEMBL12646995 | 0.83 | CSF1R (0.52) | CDC7CDK2VNN1CSF1RKIT | |
| SCHEMBL12252445 | 0.83 | MAP2K1 (0.43) | CDC7CCNE1CDK2DBF4VNN1 | |
| SCHEMBL1268072 | 0.82 | CLK1 (0.50) | CDC7CCNE1CDK2DBF4VNN1 | |
| SCHEMBL878837 | 0.80 | CSF1R (0.68) | CDC7CDK2VNN1CSF1RKIT | |
| SCHEMBL878889 | 0.80 | HDAC3 (0.44) | CSF1RKITCYP3A4CYP2C19KDR | |
| SCHEMBL858185 | 0.79 | HCAR3 (0.54) | CCNE1CDK2CSF1RKITKDR | |
| SCHEMBL1267559 | 0.79 | CSF1R (0.69) | CDC7CCNE1CDK2DBF4CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9169250-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169250-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC | 2012-12-06 | — | — | US | disclosed |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC | 2012-12-06 | — | — | US | disclosed |
| US-20110230482-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY | PLEXXIKON INC. | 2011-09-22 | — | — | US | disclosed |
| US-7893075-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893075-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| CN-101605787-A | Compounds that modulate c-fms and/or c-kit activity and uses thereof | PLEXXIKON INC (US) | 2009-12-16 | — | — | CN | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CDC7 280/4885CCNE1 1393/4885CDK2 219/4885 |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | KIT, FLT3, FLT1 | CDC7 280/4885CCNE1 1393/4885CDK2 219/4885 |
| US-20120309756-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CDC7 280/4885CCNE1 1393/4885CDK2 219/4885 |
| US-20110230482-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY | KIT, FLT3, FER | CDC7 111/4885CCNE1 1212/4885CDK2 137/4885 |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CDC7 280/4885CCNE1 1393/4885CDK2 219/4885 |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CDC7 242/4885CCNE1 1202/4885CDK2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.